CCM
VERV

CAAS Capital Management’s Verve Therapeutics VERV Stock Holding History

CAAS Capital Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-26,000
Closed -$503K – 934
2022
Q4 		$503K Buy
+26,000
New +$689K 0.03% 441
2021
Q4 		– Sell
-15,000
Closed -$705K – 1061
2021
Q3 		$705K Hold
15,000
– – 0.01% 559
2021
Q2 		$904K Buy
+15,000
New +$623K 0.02% 605

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

CAAS Capital Management's VERV Position: Q1 2023 in Review

CAAS Capital Management sold out of Verve Therapeutics (VERV) in Q1 2023, closing a stake of 26,000 shares — an estimated $503K sold.

CAAS Capital Management first reported a position in VERV in Q2 2021 and held it in 3 quarters. The position peaked at $904K in Q2 2021. 125 funds tracked by Wall St. Rank hold VERV as of Q1 2023.

  • CAAS Capital Management reported no remaining Verve Therapeutics position as of Q1 2023 after selling out during the quarter.
  • CAAS Capital Management sold 26,000 Verve Therapeutics shares in Q1 2023, an estimated $503K.
  • CAAS Capital Management first reported a position in Verve Therapeutics in Q2 2021 and held it in 3 quarters.
  • CAAS Capital Management's Verve Therapeutics position peaked at $904K in Q2 2021.
  • 125 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2023.

Based on CAAS Capital Management's 13F filing for Q1 2023, filed 15 May 2023.